Mostrar el registro sencillo del ítem

dc.contributor.author
Fuentes Mejia, Monserrat  
dc.contributor.author
Fallico, Maximiliano José  
dc.contributor.author
Talevi, Alan  
dc.contributor.author
Gavernet, Luciana  
dc.contributor.author
Orozco Suárez, Sandra A.  
dc.contributor.author
Rocha, Luisa  
dc.date.available
2025-10-03T12:20:06Z  
dc.date.issued
2025-09  
dc.identifier.citation
Fuentes Mejia, Monserrat; Fallico, Maximiliano José; Talevi, Alan; Gavernet, Luciana; Orozco Suárez, Sandra A.; et al.; Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model; Frontiers Media; Frontiers in Pharmacology; 16; 9-2025; 1-11  
dc.identifier.issn
1663-9812  
dc.identifier.uri
http://hdl.handle.net/11336/272723  
dc.description.abstract
Drug resistance affects 30% of patients with epilepsy. Cannabidiol (CBD)decreases the expression of drug-resistant seizures in specific syndromes.However, it is unknown if CBD prevents the development of drug-resistantcondition in epilepsy. This research was conducted to investigate ifsubchronic administration of CBD with sodium channel blockers modifies themortality associated with clonic-tonic seizures and the development of the drug-resistant phenotype induced by subchronic administration of 3-mercaptopropionic acid (3-MP) in rats. These effects were compared withthose elicited by antiseizure medications acting on the GABAA receptors. MaleWistar rats were used to evaluate CBD combined with different antiseizuremedications (phenobarbital, diazepam, valproic acid, lamotrigine andoxcarbazepine) during the repetitive administration of 3-MP. The mortalityrate and development of drug-resistant seizures were estimated.Computational experiments explored interactions between CBD and sodiumchannel blockers in the NaV1.7 receptor. Subchronic administration of CBD alonedid not modify neither the mortality rate nor the development of drug-resistantseizures. CBD combined with phenobarbital or diazepam reduced the mortalityrate and prevalence of drug-resistant seizures. In contrast, coadministration ofCBD with valproic acid or lamotrigine did not modify neither the mortality rate northe expression of drug-resistant seizures. Contrariwise, combining CBD withoxcarbazepine at ED50 increases the incidence of drug-resistant seizures.Computational experiments suggested that CBD acting on NaV1.7 interfereswith the action of sodium channel blockers and precludes their inhibitoryeffects. Our results indicate that repeated administration of CBD withGABAergic antiseizure medications, but not sodium channel blockers,decreases the mortality and prevents the development of the drug-resistantphenotype induced by repeatedly provoked severe seizures.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Frontiers Media  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
DRUG RESISTANCE  
dc.subject
SEIZURES  
dc.subject
CANNABIDIOL  
dc.subject
GABAERGIC DRUGS  
dc.subject
SODIUM CHANNEL BLOCKERS  
dc.subject.classification
Farmacología y Farmacia  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2025-10-03T11:39:28Z  
dc.journal.volume
16  
dc.journal.pagination
1-11  
dc.journal.pais
Suiza  
dc.description.fil
Fil: Fuentes Mejia, Monserrat. No especifíca;  
dc.description.fil
Fil: Fallico, Maximiliano José. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina  
dc.description.fil
Fil: Talevi, Alan. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina  
dc.description.fil
Fil: Gavernet, Luciana. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina  
dc.description.fil
Fil: Orozco Suárez, Sandra A.. Hospital, “Dr. Bernardo Sepúlveda"; México  
dc.description.fil
Fil: Rocha, Luisa. No especifíca;  
dc.journal.title
Frontiers in Pharmacology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fphar.2025.1644018/full  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fphar.2025.1644018